http://www.engeneinc.com () —
enGene Inc., a privately held biotechnology company developing an
innovative platform technology to deliver nucleotides (DNA or siRNA)
to mucosal tissue for treating a variety of diseases, announced today
that Dr. Anthony Cheung, co-founder and Chief Scientific Officer, will
give an oral presentation on the Company's compelling pre-clinical
data on inflammatory bowel disease (IBD) at the 2010 Advances in IBD -
Crohn's & Colitis Foundation's Clinical & Research Conference, being
held on December 9-12, 2010 at the Westin Diplomat Hotel in Hollywood,
FL.
Dr. Cheung's presentation, entitled, "Successful treatment of
experimental colitis by a nanoparticle gene delivery system that
localizes expression of interleukin-10 (IL-10) to the colon", will
take place at 9:25am, December 11th during the Adaptive Immunity in
IBD session.
"The role of IL-10 as a potent anti-inflammatory agent has been well
documented in both animal models and human studies," said Dr. Scott
Plevy, Assoc. Prof. of Medicine, Microbiology and Immunology at the U.
of North Carolina School of Medicine and co-author of the abstract. "A
major challenge has always been in the effective delivery of IL-10 -
focusing its concentration at the site of disease and minimizing its
circulation throughout the body. With this in mind, enGene's
technology holds significant promise as a treatment for IBD as well as
other gastrointestinal diseases."
More about enGene
enGene Inc. has developed a highly flexible, biopolymer-based
nucleotide (DNA and siRNA) delivery technology targeting mucosal
tissues to treat numerous prevalent, chronic diseases via the
induction or suppression of protein expression levels. Our platform
technology has the ability to significantly impact diseases of mucosal
tissues such as the gastrointestinal tract, lung and bladder as well
as provide systemic release of proteins from the gut to treat
diabetes, anemia, hemophilia and others. The two lead programs are the
localized delivery of an anti-inflammatory cytokine, IL-10, for
treating Inflammatory Bowel Disease and delivery of insulin in a
physiologic, meal-dependent fashion to regulate blood glucose levels.
For more information please visit www.engeneinc.com
(http://www.engeneinc.com) .